Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices 11557 

investigation. The Commission is 

soliciting submissions on public interest 

issues raised by the recommended relief 

should the Commission find a violation. 

This notice is soliciting comments from 

the public only. 

FOR FURTHER INFORMATION CONTACT: 

Benjamin S. Richards, Esq., Office of the 

General Counsel, U.S. International 

Trade Commission, 500 E Street SW, 

Washington, DC 20436, telephone (202) 

708–5453. Copies of non-confidential 

documents filed in connection with this 

investigation may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. For help 

accessing EDIS, please email 

EDIS3Help@usitc.gov. General 

information concerning the Commission 

may also be obtained by accessing its 

internet server at https://www.usitc.gov. 

Hearing-impaired persons are advised 

that information on this matter can be 

obtained by contacting the 

Commission’s TDD terminal on (202) 

205–1810. 

SUPPLEMENTARY INFORMATION: Parties are 

to file public interest submissions 

pursuant to 19 CFR 210.50(a)(4). Section 

337 of the Tariff Act of 1930 provides 

that, if the Commission finds a 

violation, it shall exclude the articles 

concerned from the United States: 

unless, after considering the effect of such 

exclusion upon the public health and 

welfare, competitive conditions in the United 

States economy, the production of like or 

directly competitive articles in the United 

States, and United States consumers, it finds 

that such articles should not be excluded 

from entry. 

19 U.S.C. 1337(d)(1). A similar 

provision applies to cease and desist 

orders. 19 U.S.C. 1337(f)(1). 

The Commission is soliciting 

submissions on public interest issues 

raised by the recommended relief 

should the Commission find a violation, 

specifically: A limited exclusion order 

directed to certain collapsible and 

portable furniture imported, sold for 

importation, and/or sold after 

importation by respondents Denovo 

Brands, LLC; Zhenli (Zhangzhou) 

Industrial Co., Ltd. (‘‘Denovo’’); Meike 

(Qingdao) Leisure Products Co., Ltd.; 

Westfield Outdoor, Inc. d/b/a Westfield 

Outdoors (‘‘Westfield’’); and MacSports 

Inc. (‘‘MacSports’’); and cease and desist 

orders directed to Denovo, Westfield, 

and MacSports. 

The Commission is interested in 

further development of the record on 

the public interest in this investigation. 

Accordingly, members of the public are 

invited to file submissions of no more 

than five (5) pages, inclusive of 

attachments, concerning the public 

interest in light of the ALJ’s 

Recommended Determination on 

Remedy and Bonding issued in this 

investigation on February 18, 2021. 

Comments should address whether 

issuance of the recommended remedial 

orders in this investigation, should the 

Commission find a violation, would 

affect the public health and welfare in 

the United States, competitive 

conditions in the United States 

economy, the production of like or 

directly competitive articles in the 

United States, or United States 

consumers. 

In particular, the Commission is 

interested in comments that: 

(i) explain how the articles potentially 

subject to the recommended remedial 

orders are used in the United States; 

(ii) identify any public health, safety, 

or welfare concerns in the United States 

relating to the recommended orders; 

(iii) identify like or directly 

competitive articles that complainant, 

its licensees, or third parties make in the 

United States which could replace the 

subject articles if they were to be 

excluded; 

(iv) indicate whether complainant, 

complainant’s licensees, and/or thirdparty suppliers have the capacity to 

replace the volume of articles 

potentially subject to the recommended 

orders within a commercially 

reasonable time; and 

(v) explain how the recommended 

orders would impact consumers in the 

United States. 

Written submissions must be filed no 

later than by close of business on March 

22, 2021. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above. The Commission’s paper 

filing requirements in 19 CFR 210.4(f) 

are currently waived. 85 FR 15798 

(March 19, 2020). Submissions should 

refer to the investigation number (‘‘Inv. 

No. 337–TA–1178’’) in a prominent 

place on the cover page and/or the first 

page. (See Handbook for Electronic 

Filing Procedures, https://

www.usitc.gov/documents/handbook_

on_filing_procedures.pdf.) Persons with 

questions regarding filing should 

contact the Secretary (202–205–2000). 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) By the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. Appendix 3; or (ii) by U.S. 

government employees and contract 

personnel, solely for cybersecurity 

purposes. All contract personnel will 

sign appropriate nondisclosure 

agreements. All nonconfidential written 

submissions will be available for public 

inspection on EDIS. 

This action is taken under the 

authority of section 337 of the Tariff Act 

of 1930, as amended (19 U.S.C. 1337), 

and in Part 210 of the Commission’s 

Rules of Practice and Procedure (19 CFR 

part 210). 

By order of the Commission. 

Issued: February 19, 2021. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2021–03855 Filed 2–24–21; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–789] 

Bulk Manufacturer of Controlled 

Substances Application: Chattem 

Chemicals 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Chattem Chemicals has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTARY INFORMATION listed 

below for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before April 26, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

April 26, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

11558 Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on July 20, 2020, Chattem 

Chemicals 3801 Saint Elmo Avenue, 

Chattanooga, Tennessee 37409, applied 

to be registered as a bulk manufacturer 

of the following basic class(es) of 

controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric Acid .... 2010 I 

Marihuana ................................. 7360 I 

Tetrahydrocannabinols ............. 7370 I 

4-Methoxyamphetamine ........... 7411 I 

Dihydromorphine ....................... 9145 I 

Norlevorphanol .......................... 9634 I 

Amphetamine ............................ 1100 II 

Methamphetamine .................... 1105 II 

Lisdexamfetamine ..................... 1205 II 

Methylphenidate ........................ 1724 II 

ANPP (4-Anilino-N-phenethyl-4- 

piperidine).

8333 II 

Phenylacetone .......................... 8501 II 

Cocaine ..................................... 9041 II 

Codeine ..................................... 9050 II 

Dihydrocodeine ......................... 9120 II 

Oxycodone ................................ 9143 II 

Hydromorphone ........................ 9150 II 

Hydrocodone ............................. 9193 II 

Levorphanol .............................. 9220 II 

Meperidine ................................ 9230 II 

Meperidine intermediate–A ....... 9232 II 

Meperidine intermediate–B ....... 9233 II 

Meperidine intermediate–C ....... 9234 II 

Methadone ................................ 9250 II 

Methadone intermediate ........... 9254 II 

Morphine ................................... 9300 II 

Oripavine ................................... 9330 II 

Thebaine ................................... 9333 II 

Opium, powdered ..................... 9639 II 

Opium, granulated .................... 9640 II 

Oxymorphone ........................... 9652 II 

Noroxymorphone ...................... 9668 II 

Racemethorphan ...................... 9732 II 

Alfentanil ................................... 9737 II 

Remifentanil .............................. 9739 II 

Sufentanil .................................. 9740 II 

Tapentadol ................................ 9780 II 

Fentanyl .................................... 9801 II 

The company plans to manufacturer 

the listed controlled substances in bulk 

for distribution and sale to its 

customers. 

In reference to drug code 7360 

(Marihuana) and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as a synthetic. No other activities for 

this drug code are authorized for this 

registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–03836 Filed 2–24–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–791] 

Bulk Manufacturer of Controlled 

Substances Application: S&B Pharma, 

Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: S&B Pharma, Inc., has applied 

to be registered as a bulk manufacturer 

of basic class(es) of controlled 

substance(s). Refer to Supplemental 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before April 26, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

April 26, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on November 11, 2020, 

S&B Pharma, Inc., 405 South Motor 

Avenue, Azusa, California 91702–3232, 

applied to be registered as an bulk 

manufacturer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric Acid .... 7360 I 

Tetrahydrocannabinols ............. 7370 I 

Amphetamine ............................ 1100 II 

Methamphetamine .................... 1105 II 

Lisdexamfetamine ..................... 1205 II 

Methylphenidate ........................ 1724 II 

Pentobarbital ............................. 2270 II 

4-Anilino-N-phenethyl-4-piperidine (ANPP).8333 II 

Tapentadol ................................ 9780 II 

Fentanyl .................................... 9801 II 

The company plans to manufacture 

the listed controlled substances in bulk 

for use in product development and for 

commercial sales to its customers. In 

reference to drug code 7360 (Marihuana) 

and 7370 (Tetrahydrocannabinols), the 

company plans to bulk manufacture 

both as synthetic substances. No other 

activity for these drug codes is 

authorized for this registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–03837 Filed 2–24–21; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA798] 

Importer of Controlled Substances 

Application: Myonex Inc 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Myonex Inc has applied to be 

registered as an importer of basic 

class(es) of controlled substance(s). 

Refer to Supplemental Information 

listed below for further drug 

information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before March 29, 2021. Such persons 

may also file a written request for a 

hearing on the application on or before 

March 29, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for a hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on January 6, 2021, 

Myonex Inc, 48 East Main Street, 

Norristown, Pennsylvania 19401–4915, 

applied to be registered as an importer 

of the following basic class(es) of 

controlled substance(s): 

Controlled substance Drug 

code Schedule 

Amphetamine ................. 1100 II 

Lisdexamfetamine .......... 1205 II 

Methylphenidate ............. 1724 II